Prevention and treatment of skin mycotic infections, including foot mycoses, inguinal epidermophytosis (tinea cruris), mycotic lesions of smooth skin (tinea corporis), caused by dermatophytes such as Trichophyton (including Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton verrucosum, Trichophyton violaceum), Microsporum canis and Epidermophyton floccosum.
Yeast infections of skin, mainly those caused by the genus Candida (e.g. Candida albicans), in particular diaper.
Scaly skin disease (Pityriasis versicolor) caused by Pityrosporum orbiculare (also known as Malassezia furfur).
Conditions arising from deficiency of ascorbic and folic acid: macrocytic anemia, sprue. Anemia and leukopenia caused by medicinal substances and ionizing radiation, with anemia arising from resection of the stomach and intestines, liver disease, dystrophy.
Conditions of increased need for ascorbic and folic acids: pregnancy (especially multifetal pregnancy, against the background of nicotine or drug addiction), lactation period.
A and E avitaminosis.
In complex therapy:
- skin lesions and diseases accompanied by tissue trophic disorders (psoriasis, some forms of eczema, ichthyosis, seborrheic dermatitis);
- obliterating endarteritis.
Prevention of recurrence of paroxysmal rhythm disorders: life-threatening ventricular arrhythmias (including ventricular tachycardia and ventricular fibrillation); supraventricular arrhythmias (including in case of organic heart diseases, as well as in case of ineffectiveness or impossibility to use other antiarrhythmic therapy); confirmed attacks of recurrent stable supraventricular paroxysmal tachycardia for patients with Wolf-Parkinson-White syndrome; ciliary arrhythmia (atrial fibrillation) and atrial fluttering.
Prevention of sudden death due to arrhythmia for high-risk patients: patients after a recent myocardial infarction with more than 10/h of ventricular extrasystoles, with clinical signs of chronic heart failure (CHF) and a left ventricular ejection fraction (LV) of less than 40%.
Cognitive impairment in organic brain damage, including the effects of neuroinfections, head injuries and neurotic disorders;
in extrapyramidal hyperkinesis, for patients with hereditary diseases of nervous system in combination with therapy;
as a corrector in case of side effects of neuroleptic agents, in case of neuroleptic extrapyramidal syndrome (hyperkinetic and akinetic), as a part of complex therapy in case of cerebral organic insufficiency in patients with schizophrenia;
epilepsy with retardation of mental processes in complex therapy with anticonvulsants;
Psychoemotional overloads, reduction of mental and physical performance, to improve concentration and memory;
neurogenic disorders of urination (pollakiuria, imperative urges, imperative urinary incontinence, enuresis);
children with delayed development (mental, speech, motor or their combination), including against the background of perinatal encephalopathy and in children with various forms of cerebral palsy;
children with hyperkinetic disorders (hyperactivity syndrome with attention deficit);
children with neurosis-like conditions (ticks; stuttering, mainly in a clonic form).
Symptomatic treatment of osteoarthritis;
Symptomatic treatment of rheumatoid arthritis;
Symptomatic treatment of ankylosing spondylitis (Bekhterev's disease).
Infectious and inflammatory diseases of periodontal and oral cavity mucosa:
acute and chronic gingivitis;
acute ulcerative necrotic gingivitis of Vincennes;
acute and chronic periodontitis;
periodontal disease complicated by gingivitis;
inflammation of the oral mucous membrane when wearing prostheses;
post-extraction alveolitis (inflammation of the well after tooth extraction);
Periodontal abscess periodontitis (as part of combined therapy).